Earnings Releases·Nov 13, 2026, 5:19 PM ET

Cingulate Inc. — Third Quarter 2026 Earnings Summary

Cash and cash equivalents rose to $23.2 million as of September 30, 2026, from $11.0 million at year-end 2025, while total stockholders' equity increased to $20.8 million from $2.5 million; however, net loss widened to $7.7 million for the quarter (vs. $7.3 million in 2025) and $22.9 million for the nine months (vs. $16.2 million in 2025).
The Company expects to resubmit the New Drug Application (NDA) for its lead asset CTx-1301 between December 2026 and January 2027, with current cash reserves sufficient to fund operations and regulatory costs into mid-2027.
Significant capital was raised during the first nine months of 2026, including a $12.0 million private placement and $22.5 million via At-the-Market and Purchase Agreements, offsetting $20.4 million in cash used for operations.
Management confirmed the FDA's June 2026 Complete Response Letter raised no safety or efficacy concerns regarding CTx-1301, with CMC work substantially completed, while SG&A expenses surged 116.6% year-over-year for the nine-month period to $14.2 million.